Public Employees Retirement Association of Colorado Sells 2,698 Shares of Edwards Lifesciences Corporation (EW)

Public Employees Retirement Association of Colorado cut its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 6.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 38,908 shares of the medical research company’s stock after selling 2,698 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Edwards Lifesciences Corporation were worth $4,253,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Capital Asset Advisory Services LLC acquired a new stake in Edwards Lifesciences Corporation in the second quarter valued at $575,000. Factory Mutual Insurance Co. acquired a new stake in Edwards Lifesciences Corporation in the second quarter valued at $13,716,000. Atria Investments LLC lifted its holdings in Edwards Lifesciences Corporation by 3.0% in the second quarter. Atria Investments LLC now owns 3,856 shares of the medical research company’s stock valued at $456,000 after acquiring an additional 113 shares during the period. Iberiabank Corp lifted its holdings in Edwards Lifesciences Corporation by 10.0% in the second quarter. Iberiabank Corp now owns 13,197 shares of the medical research company’s stock valued at $1,560,000 after acquiring an additional 1,200 shares during the period. Finally, Pure Financial Advisors Inc. lifted its holdings in Edwards Lifesciences Corporation by 14.0% in the second quarter. Pure Financial Advisors Inc. now owns 4,693 shares of the medical research company’s stock valued at $555,000 after acquiring an additional 575 shares during the period. 82.32% of the stock is owned by hedge funds and other institutional investors.

Shares of Edwards Lifesciences Corporation (NYSE EW) opened at $102.72 on Monday. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.49 and a quick ratio of 2.76. The firm has a market cap of $21,737.60, a P/E ratio of 28.45, a PEG ratio of 1.84 and a beta of 0.46.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.02). The business had revenue of $821.50 million during the quarter, compared to analysts’ expectations of $833.85 million. Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.68 EPS. analysts forecast that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Public Employees Retirement Association of Colorado Sells 2,698 Shares of Edwards Lifesciences Corporation (EW)” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.com-unik.info/2017/11/06/public-employees-retirement-association-of-colorado-sells-2698-shares-of-edwards-lifesciences-corporation-ew.html.

In other news, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences Corporation stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $112.15, for a total value of $594,395.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $111.81, for a total value of $2,119,917.60. The disclosure for this sale can be found here. Insiders sold a total of 171,480 shares of company stock worth $18,855,915 over the last ninety days. Corporate insiders own 2.13% of the company’s stock.

A number of equities research analysts have commented on EW shares. Royal Bank Of Canada reissued a “buy” rating and issued a $130.00 target price on shares of Edwards Lifesciences Corporation in a report on Friday, July 28th. Stifel Nicolaus reaffirmed a “buy” rating and set a $130.00 price target (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Zacks Investment Research raised Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price target for the company in a research note on Tuesday, July 18th. SunTrust Banks, Inc. lifted their price target on Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a research note on Monday, July 17th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $135.00 price target (down previously from $155.00) on shares of Edwards Lifesciences Corporation in a research note on Wednesday, October 25th. Seven research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Edwards Lifesciences Corporation has a consensus rating of “Buy” and a consensus price target of $125.17.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

What are top analysts saying about Edwards Lifesciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Edwards Lifesciences Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit